Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

Charles University, Czech Republic

Status: Completed

Conditions: Hepatitis C, Chronic

Study type: Observational

Funder types: Other

Identifiers

NCT01112033

BLVRA1

Details and patient eligibility

About

In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in HCV infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.

Full description

1. To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls.
2. To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically naïve HCV patients, during/after standard antiviral therapy and healthy controls.
3. To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy controls.

Enrollment: 113 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

BLVRA expression study

• Therapeutically naïve HCV patients undergoing antiviral treatment with peg-interferon plus ribavirin combination therapy

BLVRA genetic polymorphisms study

• HCV infected patients prior, during, after or without antiviral therapy

Exclusion criteria

• Co-infection with HAV, HBV and HIV
• Disorders of heme metabolism

Trial design

113 participants in 1 patient group

chronic HCV infection

Description:

The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.